Selexis names Yemi Onakunle as vp of strategic and market development

Former Diosynth and Lonza executive joins Swiss life science company

Geneva, Switzerland-based Selexis has hired Yemi Onakunle as vice president of strategic and market development. He will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets.

Onakunle has more than 15 years' experience in drug manufacturing and cell line development. Prior to joining Selexis, he was director of commercial development at Diosynth RTP and associate director of business development at Lonza Custom Manufacturing.

More recently, Onakunle was head of sales and marketing at Bachem Americas, a contract manufacturing organisation focusing on peptides and complex organic molecules.

Onakunle is a member of the board of directors of VLP Biotech, a vaccine development company based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies.

You may also like

Research & Development

Faron links up with Selexis to progress development of cancer antibody

Under the agreement, Faron will have access to the Selexis SUREtechnology platform and SURE CHO-M cell line
Manufacturing

JHL Biotech and Selexis form biologic drug development alliance

Will provide seamless services from cell line development to cGMP manufacturing
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Subscribe now